ABCB4 mutations underlie hormonal cholestasis but not pediatric idiopathic gallstones

Table 1 Characteristics of young women with low phospholipid-associated cholelithiasis syndrome and proven ABCB4 mutations

Patient ID	Year of birth	Age at cholecystectomy (yr)	Age at liver biopsy (yr)	Age at pregnancies (yr)	Age (yr), contraceptive, complication
I	1980	20	19, periportal fibrosis	Nulliparous	18 Minisiston, withdrawn for CIC
					22 Mercilon, withdrawn for CIC
II	1978	17	21, periportal fibrosis	Nulliparous	18 Tri-regol, withdrawn for CIC
III	1973	22	22, periportal fibrosis	30, with ICP	20-22 Cilest, withdrawn for CIC
IV	1967	28	31, normal histology	19, without ICP	28 Tri-regol, withdrawn for CIC
					39-now Lunafem, tolerated
V	1973	20	20, periportal fibrosis	23, without ICP	19-?, withdrawn for CIC
				32, without ICP	24-31 Marvelon, tolerated
					32-now Mirena, permanent pruritus, GGT twice normal

Chemical composition of contraceptives: (1) Minisiston (Jenapharm, Jena, Germany): ethinylestradiol 0.030 mg; levonorgestrel 0.125 mg; (2) Mercilon (Organon, Oss, The Netherlands): ethinylestradiol 0.020 mg; desogestrel 0.150 mg; (3) Tri-regol (Chemical Works of Gedeon Richter, Budapest, Hungary): ethinylestradiol 0.030 - 0.040 - 0.030 mg; levonorgestrel 0.050 - 0.075 - 0.125 mg; (4) Cilest (Janssen Pharmaceutica, Beerse, Belgium): ethinylestradiol 0.035 - 0.035 - 0 mg; norgestimate 0.250 - 0.250 - 0 mg; (5) Lunafem (Bayer Schering Pharma, Berlin, Germany): ethinylestradiol 0.020 mg; gestodene 0.075 mg; (6) Marvelon (Organon, Oss, The Netherlands): ethinylestradiol 0.030 mg; desogestrel 0.150 mg; (7) Mirena (Bayer Schering Pharma, Berlin, Germany): levonorgestrel 0.020 mg. Estrogen free intrauterine application. CIC: Contraceptive-induced cholestasis.